Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2025-03-25 00:00:00 ET · period of report 2025-03-21 · accession 0001140361-25-010234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2025-03-25 | 2025-03-21 | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.00 | -174 | 2.82M | -0.0% | -$1,740 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-21 | S | D | 174 | $10.00 | 2,824,844 | I By Spouse | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.005. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |